Patent

Intellectual Property Portfolio

CgA Therapeuticals, Inc. is developing a broad intellectual property portfolio centered on catestatin (CST), next-generation CST peptidomimetics, Boolean implication network technologies, and related therapeutic and computational innovations.

The portfolio originates from discoveries made at the University of California San Diego and VA San Diego Healthcare System and encompasses therapeutic applications of CST and related compounds across cardiometabolic disease, neurodegeneration and cognitive decline, and cancer, together with computational methods for detecting latent biological states.

CgA Therapeuticals has entered into an exclusive license agreement with The Regents of the University of California, represented by UC San Diego, covering defined patent rights for specified therapeutic technologies. The licensed patent rights extend worldwide to the extent corresponding patent rights exist and include rights to develop, manufacture, use, commercialize, and sublicense licensed products, subject to the terms of the agreement and applicable U.S. Government rights.

Licensed Patent Families

Catestatin for Cardiometabolic Disease

U.S. Patent No. 9,572,862 B2
Title: Methods for Promoting Lipolysis and Oxidation in Liver and Adipose Tissue Using Catestatin
Issued: February 21, 2017
Inventors: Sushil K. Mahata, and Gautam K. Bandyopadgyay

This issued U.S. patent covers therapeutic use of CST to promote lipolysis and fatty-acid oxidation in liver and adipose tissue, providing foundational intellectual property for the development of CST-based therapies targeting obesity and associated metabolic disorders. The patent is included in the licensed portfolio as UC San Diego Case SD2012-314.

Catestatin for Neurodegeneration and Cognitive Decline

International Patent Application: PCT/US2024/053684
Title: Compositions & Methods to Treat Neurodegeneration and Cognitive Decline
Filed: October 30, 2024
Inventors: Sushil K. Mahata, and Suborno Jati

This patent family encompasses therapeutic applications arising from the discovery that CST and related therapeutic approaches can target mechanisms associated with neurodegeneration and cognitive decline, including applications relevant to Alzheimer's disease and related tauopathies. The application represents an important expansion of the CST platform from cardiometabolic disease into neurotherapeutics and is included in the licensed portfolio as UC San Diego Case SD2024-374.

CST and Peptidomimetics for Cancer

U.S. Provisional Patent Application No. 63/751,092
Title: An Endogenous Peptide, Peptidomimetic and Its Small Molecule Mimetic as Novel Anticancer Agents
Filed: January 29, 2025
Inventors: Sushil K. Mahata, Soo Jin Park, and Satadeepa Kal

This invention extends the CST therapeutic platform into oncology and encompasses CST, peptidomimetic approaches, and related small-molecule strategies investigated for anticancer activity. It is included in the licensed portfolio as UC San Diego Case SD2024-371.

Boolean Implication Networks for Detecting Latent States

International Patent Application: PCT/US2026/032192 Title: BOOLEAN IMPLICATION NETWORK SYSTEMS AND METHODS FOR DETECTING LATENT STATES Filed: June 10, 2026 Inventors: Debashis Sahoo, Sushil K. Mahata, and Suborno Jati

This international patent application covers Boolean implication network systems and methods for detecting latent states. The executed worldwide assignment transfers the inventors' right, title, and interest in the invention and associated U.S. and foreign patent rights to The Regents of the University of California. The technology provides an intellectual-property foundation for computational identification and characterization of latent biological or disease states, complementing the company's therapeutic discovery strategy.

Note: This filing is listed here as part of the broader innovation portfolio. The documents reviewed for this update establish assignment to The Regents of the University of California; they do not, by themselves, establish that this 2026 filing is included within CgA Therapeuticals' existing exclusive license.

Next-Generation Therapeutic & Discovery Platform

CgA Therapeuticals is building upon these foundational inventions by developing native CST, naturally occurring human CST variants, retro-inverso CST (RI-CST), D-amino-acid derivatives, peptidomimetics, and other next-generation therapeutic candidates, while integrating computational approaches that can identify disease-associated and resilient biological states.

The objective is to create an integrated discovery and therapeutic platform combining endogenous CST biology with improved stability, pharmacokinetics, bioavailability, dosing characteristics, and therapeutic efficacy, supported by systems-level approaches for target and disease-state discovery.

The company's intellectual property and development strategy spans multiple areas, including:

  • Cardiometabolic disorders
  • Gastroparesis and gastrointestinal dysfunction
  • Alzheimer's disease and related neurodegenerative disorders
  • Cancer
  • Computational identification of latent biological and disease states
  • Other diseases associated with metabolic, inflammatory, and cellular dysfunction

Exclusive License and Commercial Development

Under its executed license agreement with The Regents of the University of California, CgA Therapeuticals holds an exclusive license under the specified Patent Rights for therapeutic applications, subject to the terms of the agreement, applicable government rights, and UC San Diego/VA institutional arrangements. The agreement also provides CgA Therapeuticals with the ability to grant sublicenses while the patent license remains exclusive.

This intellectual property position provides a foundation for CgA Therapeuticals to advance CST-based discoveries from academic innovation through preclinical development and toward clinical translation and commercialization. The newly filed Boolean implication network patent application broadens the underlying innovation landscape; any commercial rights of CgA Therapeuticals to that filing will depend on the applicable licensing arrangements.